DSIP Research & Studies
Part of the full DSIP guide - a endogenous amphiphilic neuropeptide reference compound, identity-verified with a COA on every vial.
In brief
The investigational record for DSIP, as captured in the provided entry, centers on a foundational review and three named research areas. This spoke attributes each line of inquiry only to the sources supplied and frames every claim as model-system research rather than clinical finding.
The detail
A closer look
01
The anchoring review
The single citation in the provided record is Graf, M. V. and Kastin, A. J., "Delta-sleep-inducing peptide (DSIP): a review," published in Neuroscience & Biobehavioral Reviews in 1984 (DOI 10.1016/0149-7634(84)90022-8; PMID 6504414). As a review, this source consolidates the early characterization of the peptide and situates it within sleep, stress-resistance, and signaling research. All higher-level mechanistic framing in this reference set traces back to the body of work summarized by such literature, and no additional studies, PMIDs, or DOIs are introduced here.
02
Three named research axes
The entry enumerates three research areas. First, MAPK/ERK-cascade signaling models, where the peptide's reported association with inhibition of Raf-1 activation and downstream ERK phosphorylation is examined. Second, stress-resistance and neuro-protective assays, consistent with the peptide's original isolation context and its reported stress-protective and anti-seizure observations. Third, enkephalin-opioid-receptor interaction studies, which probe how DSIP modulates an endogenous opioid signaling pathway. These three axes define the investigational scope reflected in the provided data.
03
Origin and identity facts under study
Supporting the research framing are documented identity facts: DSIP is a nonapeptide (9 amino acids), with a molecular weight of 848.81 g/mol, first isolated in 1977 from rabbit cerebral venous blood (source hints: Wikipedia/CPC Scientific, ChemicalBook, and the DSIP literature). The isolation from cerebral venous blood during induced sleep is the historical anchor that gave the peptide its name and seeded the sleep-and-stress lines of investigation. These facts are reference points for laboratory characterization, not endpoints of efficacy testing.
04
Boundaries of the evidence
The provided entry is explicit that DSIP's reported activities (stress-protective, anti-seizure, immunomodulating) are mechanistic, model-system observations and are not statements of clinical efficacy. Researchers using this reference should therefore treat the literature as describing signaling behavior and biochemical homology in controlled systems. No human outcome data, dosing protocol, or therapeutic conclusion is supported by the supplied sources, and none should be inferred from them.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. DSIP is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.